IN THIS ISSUE, Whelan and Hahn review the issues surrounding the optimal use of metered-dose inhalers (MDls). Aerosol delivery of bronchodilators, particularly MOl use, has been both an important and controversial therapeutic modality in asthma for decades. The National Heart, Lung, and Blood Institute's National Asthma Education Program Expert Panel on the Management of Asthma has released recommendations that further emphasize the need for all health professionals to learn more about asthma and the drugs used in its management. The Panel's report emphasizes (1) patient education, (2) home monitoring with peak flow meters, and (3) the increased use of antiinflammatory drugs (i.e., cromolyn and inhaled corticosteroids) as primary therapy for chronic asthma. I In the US, inhaled corticosteroids are available only in MOls, and cromolyn is effective only as an aerosol. A few drypowder inhalers that are breath-actuated are available and no doubt will become more plentiful following the proposed ban on the production of chlorofluorocarbons currently used as the propellants in MOls. However, the MOls represent a very important drug delivery system in the management of asthma.'
As pointed out by Whelan and Hahn, optimal delivery of drugs via MOIs is highly dependent on patient technique. Certain aspects, such as coordinating inhalation with MOl actuation, using a slow deep inhalation, and holding one's breath for four to ten seconds at the end of inhalation, have been conclusively shown to produce both improved delivery and therapeutic effect. Other aspects, such as the open-mouth technique and the use of various auxiliary spacer devices, have produced less consistent results. What accounts for these discrepancies? Recent studies may provide some insight.
Studies evaluating factors that affect airway delivery from MOIs consist of either imaging studies following inhalation of radiolabeled particles (usually Teflon) or spirometric studies following inhalation of bronchodilators.' When comparing studies, the first assumption is that all MOIs produce a similarly sized aerosol particle; therefore, data from one MOl can be extrapolated to others. However, droplets from liquid-solution MOIs (Bronkometer) vaporize more slowly than those from dry-powder suspensions (Alupent and Beclovent) and so stay larger longer. Although similar in size to drug particles, teflon particles have an increased density and so are more likely to bedeposited by impaction in large airways. All corticosteroid preparations do not exhibit the same deposition characteristics (Beclovent vs. Azmacort) nor are they similar to bronchodilators (Beclovent vs. Alupent).' Thus, extrapolating data produced from one MOl to all others can be misleading.
In a series of recent studies, Ahrens has demonstrated how insensitive improvement in spirometric testing is in determining potency differences between various beta-agonists (albuterol vs. metaproterenol) as well as between aerosol delivery methods (MOls vs. nebulizers).' Thus, it is not surprising that spirometric studies often fail to demonstrate what may be significant differences in drug delivery. Finally, auxiliary spacer devices do not produce the same changes in deposition. All spacer devices produce a significant reduction in oropharyngeal deposition; however, only the large-volume spacers (750-mL Nebuhaler and 650-mL InspirEase) significantly enhance lung delivery from MOIs.4 This is likely a result of the greater loss, because of impaction, in the smaller volume spacers. lt~ough this improved deposition has yet to be proven significant for bronchodilators utilizing spirometric testing, the majority of studies with inhaled corticosteroids demonstrate improved efficacy with large-volume spacers plus MOl over MOl alone. In addition, two recent trials have reported significantly reduced hypothalamic-pituitaryadrenal axis suppression from high-dose inhaled corticosteroid therapy (beclomethasone dipropionate 2 mg/d) that is being advocated for severe chronic asthma.v' This occurred whether the corticosteroid was delivered by the standard inhaler (50 ug/inhalation)" or the high-dose inhaler (250 ug/inhalation),' which is available in Europe and undergoing clinical testing in the US.
The most important aspect of Whelan and Hahn's analysis is that a large number of patients require instruction before they are able to use their MDIs adequately. Studies show that demonstration of proper technique is superior to just explaining or supplying reading material (package insert) and that only supplying reading material is little better than doing nothing. Who should provide the patient education? Everyone involved in the patient's care should be able to provide the demonstration: physicians, nurses, pharmacists, and respiratory therapists. Who provides the patient education for many patients? Almost no one. As Whelan and Hahn point out, many health professionals do not know how to properly use MDIs despite the fact that they have patients who are using them. Self et at. reported in 1983 that pharmacists can make a significant impact on this problem by educating patients in proper inhalation technique." Yet in 1990, this same group reported that only 13 percent of 52 randomly selected pharmacists in three cities offered to educate patients on their inhaler use. Even worse is the fmding that many pharmacists did not know the correct technique when asked by the patients and only one actually demonstrated the correct technique," Rarely do such potent, life-saving therapies lend themselves to such variable results that can so easily be remedied by such a minimal amount of patient education (5-15 minutes of patient instruction). To paraphrase Pogo, "We have met the problem and it is us." No pharmacy student should graduate without demonstrating the ability to instruct someone in the proper use of an MDI, dry-powder inhaler, or MDI plus a spacer. I hope the publication of the Expert Panel's guidelines for the management of asthma will increase the awareness in all health professionals of the need for ongoing patient education if we are to halt the rising mortality rate from asthma.
RESEARCH PRODUCTMTY AND FUNDING
Milap C. Nahata RESEARCH IS ESSENTIAL for achieving new frontiers in all disciplines. Research productivity in an academic environment (e.g., universities, institutes, hospitals) is measured by a number of factors including the number and types of presentations and publications of results, education and training of students or fellows, and research grants or contracts. The purpose of this editorial is to share some of my thoughts about the relative importance of these factors in assessing the overall impact or outcome of research productivity.
Publications are the most effective means of widely disseminating newly discovered facts within the field. Quality of published articles can be evaluated by addressing questions such as: Was the article published in a reputable, MILAP In what context, where, and how many times was the article cited by others in subsequent literature?' It is disappointing to note that 55 percent of the papers published between 1981 and 1985 have never been cited. This figure may not totally be accurate as it is based on the Institute for Scientific Information's database covering only the top science and social science journals, about 4500 of nearly 74000 scientific titles. It has been suggested, however, that 10 percent of the journals receive 90 percent of all citations, and thus have the most impact.z The quantity of publications (output) becomes important only if quality is maintained, and impact (outcome) remains significant.
The education and training of undergraduates and Pharm.D.s, as well as residents or fellows in research, con-
